Intra Cellular Therapies Inc (ITCI) Return on Investment ROI from the fourth quarter of 2024 to fourth quarter of 2023 and for the year 2024, average high and low, overall ranking from Dec 31 2024 to Dec 31 2023 - CSIMarket
Intra Cellular Therapies Inc's ROI from its fourth quarter of 2024 to the fourth quarter of 2023 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Intra Cellular Therapies Inc's ROI in the fourth quarter of 2024?
Intra Cellular Therapies Inc recorded a cumulative net loss of $-75 million during 12 months ending in the fourth quarter of 2024, resulting in a negative return on investment (ROI) of -7.3%.
Within the Healthcare sector 247 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2024 from 2923 to 3000.
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a renowned biopharmaceutical company specializing in the development and commercialization of therapeutics for central nervous system (CNS) disorders, has recently announced the appointment of Sanjeev Narula as their Executive Vice President and Chief Financial Officer. With this strategic move, ITCI aims to reinforce its leadership team and drive continued growth in the dynamic pharmaceutical industry. New CFO to Drive Financial Strategy: Sanjeev Narula, an esteemed financial executive, will assume the role of CFO at Intra-Cellular Therapies on August 12, 2024. Mr. Narula brings with him a wealth of experience and expertise in financial management, having held key positions in prominent organizations. In his new capacity, he will report directly to Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies, and will be responsible for developing and executing the company s financial strategy.
Intra-Cellular Therapies, a renowned biopharmaceutical company specializing in the development and commercialization of therapeutics for central nervous system (CNS) disorders, has made significant changes in its leadership team. The promotion of Michael Halstead, J.D. to the position of President marks a strategic move to leverage his expertise in driving various functional areas within the organization. This article explores the implications of this appointment and the potential for enhanced growth and innovation within Intra-Cellular Therapies. Enhanced Leadership to Drive Multi-Faceted Functions: As part of the restructuring, Michael Halstead, who currently serves as Executive Vice President and General Counsel, will now oversee a diverse range of functions within the company. This extensive portfolio includes legal affairs, human resources, manufacturing and supply chain, quality control, compliance, information technology, and external innovation. By consolidating these critical areas under his leadership, Halstead aims to streamline processes, increase operational efficiency, and facilitate collaboration across functional teams.
Financial Statements
Intra Cellular Therapies Inc's IV. Quarter Investments
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
